UB Paderborn / Katalog / Suche / in CDI

In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans

Handbook of experimental pharmacology, 2011-01 (201), p.403

2011

Volltextzugriff (PDF)

Investigation of the in vitro metabolism of the analgesic flupirtine

Drug metabolism and disposition, 2009-03, Vol.37 (3), p.479

2009

Volltextzugriff (PDF)

Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers

European journal of clinical pharmacology, 2007-07, Vol.63 (7), p.663-668

2007

Volltextzugriff (PDF)

Effect of levothyroxine administration on intestinal P-glycoprotein expression: Consequences for drug disposition

Clinical pharmacology and therapeutics, 2002-09, Vol.72 (3), p.256-264

2002

Volltextzugriff (PDF)

Determination of talinolol in human plasma by high performance liquid chromatography–electrospray ionization mass spectrometry: Application to pharmacokinetic study

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007-06, Vol.853 (1-2), p.275-280

2007

Volltextzugriff (PDF)

Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1

British journal of clinical pharmacology, 2015-03, Vol.79 (3), p.501-513

2015

Volltextzugriff (PDF)

Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study

Current medical research and opinion, 2012-10, Vol.28 (10), p.1617-1634

2012

Volltextzugriff (PDF)

Effects of advanced age and renal dysfunction on the single- and repeated-dose pharmacokinetics of modified-release flupirtine

International journal of clinical pharmacology and therapeutics, 2015-03, Vol.53 (3), p.247

2015

Volltextzugriff (PDF)

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

Clinical pharmacology and therapeutics, 2000-10, Vol.68 (4), p.345-355

2000

Volltextzugriff (PDF)

Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein

Clinical pharmacology and therapeutics, 2000-07, Vol.68 (1), p.6-12

2000

Volltextzugriff (PDF)

Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms

British journal of clinical pharmacology, 2006-04, Vol.61 (4), p.440-450

2006

Volltextzugriff (PDF)

Metabolism of the analgesic flupirtin in man

The FASEB journal, 2009-04, Vol.23 (S1)

2009

Volltextzugriff (PDF)

Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans

Clinical pharmacology and therapeutics, 1996-05, Vol.59 (5), p.541-549

1996

Volltextzugriff (PDF)

Variability of Intestinal Expression of P-Glycoprotein in Healthy Volunteers as Described by Absorption of Talinolol from Four Bioequivalent Tablets

Journal of pharmaceutical sciences, 2003-03, Vol.92 (3), p.604-610

2003

Volltextzugriff (PDF)

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers : Concentration- and dose-dependent absorption in vitro and in vivo

Pharmaceutical research, 1996-04, Vol.13 (4), p.514-522

1996

Volltextzugriff (PDF)

Stereoselective disposition of talinolol in man

Journal of pharmaceutical sciences, 2002-02, Vol.91 (2), p.303-311

2002

Volltextzugriff (PDF)

Registration of drug-associated lesions of the mucosa of the upper gastrointestinal tract. The problem of characterizing the health status of healthy subjects

Arzneimittel-Forschung, 2002, Vol.52 (3), p.211

2002

Volltextzugriff (PDF)

Application of quantifying scoring systems for the determination of changes in the mucosa of the upper gastrointestinal tract. A comparative study of a diclofenac effervescent tablet with conventional diclofenac preparations and acetylsalicylic acid after repeated administration

Arzneimittel-Forschung, 2002, Vol.52 (4), p.264

2002

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans

Investigation of the in vitro metabolism of the analgesic flupirtine

Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers

Effect of levothyroxine administration on intestinal P-glycoprotein expression: Consequences for drug disposition

Determination of talinolol in human plasma by high performance liquid chromatography–electrospray ionization mass spectrometry: Application to pharmacokinetic study

Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1

Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study

Effects of advanced age and renal dysfunction on the single- and repeated-dose pharmacokinetics of modified-release flupirtine

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein

Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms

Metabolism of the analgesic flupirtin in man

Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans

Variability of Intestinal Expression of P-Glycoprotein in Healthy Volunteers as Described by Absorption of Talinolol from Four Bioequivalent Tablets

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers : Concentration- and dose-dependent absorption in vitro and in vivo

Stereoselective disposition of talinolol in man

Registration of drug-associated lesions of the mucosa of the upper gastrointestinal tract. The problem of characterizing the health status of healthy subjects

Application of quantifying scoring systems for the determination of changes in the mucosa of the upper gastrointestinal tract. A comparative study of a diclofenac effervescent tablet with conventional diclofenac preparations and acetylsalicylic acid after repeated administration

Suchergebnisse filtern